Drug intelligence / Profile preview

ZN6168

Development stage: Unknown
Lead developer: Shanghai Aibo Pharmaceutical Technology
Modality: Small Molecules
Administration: Oral

Overview

ZN6168 is a small molecule inhibitor of the Hepatitis C Virus (HCV) nonstructural protein 5A (NS5A), developed by Shanghai Aibo Pharmaceutical Technology. It is designed for the treatment of chronic hepatitis C infection, functioning as a direct-acting antiviral (DAA). By targeting the NS5A protein, ZN6168 disrupts the formation of the viral replication complex and the assembly of mature virions. In clinical trials, ZN6168 is typically administered orally in combination with ZN6166, an NS3/4A protease inhibitor, to achieve a potent, interferon-free therapeutic effect across multiple HCV genotypes.

Targets

NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))

Beyond the preview

Go deeper on ZN6168.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZN6168.

Explore the full profile